Merck releases statement on FDA's Advisory Committee meeting about suvorexant

Merck (NYSE: MRK), known as MSD outside the United States and Canada, today provided the following statement after the conclusion of the Peripheral and Central Nervous System Drugs Advisory Committee meeting of the U.S. Food and Drug Administration (FDA) about suvorexant, Merck's investigational medicine to treat insomnia.

“Today's votes and discussion bring us one step closer to providing physicians with another option to help patients struggling with insomnia. We look forward to working with the FDA as the agency continues its review of our application.”

"We are excited about the potential of suvorexant as a new and different approach to treating insomnia, a serious condition that affects up to one-third of the adult population," said Darryle Schoepp, Ph.D., senior vice president and head of Neuroscience and Ophthalmology, Merck Research Laboratories. "Today's votes and discussion bring us one step closer to providing physicians with another option to help patients struggling with insomnia. We look forward to working with the FDA as the agency continues its review of our application."

If approved, suvorexant would be the first in a new class of medicines, called orexin receptor antagonists, for use in patients with insomnia, a condition characterized by difficulty falling asleep and/or staying asleep. Suvorexant's novel mechanism is distinct from current treatments. Merck researchers developed suvorexant to block the action of orexins, neurotransmitters in a specific part of the brain that help to keep a person awake. By temporarily blocking the actions of orexins, suvorexant helps to facilitate sleep.

The FDA will consider the Committee's recommendations as it completes its review of the New Drug Application (NDA) for suvorexant. The FDA is not bound by the Committee's guidance, but takes its advice into consideration when reviewing investigational medicines. Merck anticipates FDA action on suvorexant in mid-year. If approved by the FDA, suvorexant will become available after a schedule assessment and determination has been completed by the U.S. Drug Enforcement Administration, which typically takes place after FDA approval.

Source:

Merck

Advertisement

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News-Medical.Net.
Post a new comment
Post
You might also like... ×
Link found between light pollution and insomnia in older adults